Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer

PURPOSE: Combining cetuximab with chemotherapy provides clinical benefit to 60% of the patients with RAS wild-type (RAS-wt) metastatic colorectal cancer (mCRC). This pilot study investigated the efficacy of cetuximab-based chemotherapy in a sample of patients (40%) with RAS mutation (RAS-mt) in thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchahda, Mohamed, Saffroy, Raphael, Karaboué, Abdoulaye, Hamelin, Jocelyne, Innominato, Pasquale, Saliba, Faouzi, Lévi, Francis, Bosselut, Nelly, Lemoine, Antoinette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529530/
https://www.ncbi.nlm.nih.gov/pubmed/33015528
http://dx.doi.org/10.1200/PO.19.00400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529530/
https://www.ncbi.nlm.nih.gov/pubmed/33015528
http://dx.doi.org/10.1200/PO.19.00400

Ejemplares similares